Cargando…
Tissue factor-targeted lidamycin inhibits growth and metastasis of colon carcinoma
Colon cancer is the third most common cancer in the world. The overexpression of tissue factor (TF) in colon cancer cells makes it an ideal target for colon cancer therapy. The purpose of the present study was to develop a TF-targeting energized fusion protein, mlFVII-LDP-AE, which is composed of a...
Autores principales: | ZHANG, QING, LIU, XIUJUN, LI, CAIHONG, LIAO, DONGSHENG, OUYANG, ZHIGANG, ZHENG, JUNNIAN, SONG, XU |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789075/ https://www.ncbi.nlm.nih.gov/pubmed/24137414 http://dx.doi.org/10.3892/ol.2013.1437 |
Ejemplares similares
-
Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis
por: Jiang, Wen-guo, et al.
Publicado: (2013) -
Site-specific PEGylation of lidamycin and its antitumor activity
por: Li, Liang, et al.
Publicado: (2015) -
Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy
por: ZHONG, GEN-SHEN, et al.
Publicado: (2013) -
EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells
por: Sha, Ming-Quan, et al.
Publicado: (2016) -
Transarterial oily chemoembolization with lidamycin shows potent therapeutic efficacy in VX2 rabbit liver tumor
por: Zhong, Genshen, et al.
Publicado: (2015)